Norfolk, VA – According to filings with the U.S. Securities and Exchange Commission, ReAlta Life Sciences is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ulrich Thienel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ReAlta Life Sciences

At ReAlta Life Sciences, Inc. our mission is to address life-threatening medical needs through beneficial inhibition of the Complement System and Inflammatory Mechanisms. To support this mission, ReAlta has developed a new class of drugs that deploy a set of unique multi-modal therapeutic capabilities. The ReAlta technology platform, termed PIC1, is a family of over 75 engineered peptides. This platform is uniquely multi-modal, with Complement inhibition (C1), anti-inflammatory, anti-oxidant and antimicrobial capabilities. Lab and animal research show this platform has the potential to provide game-changing therapy for over 25 unmet or under-addressed medical needs.

To learn more about ReAlta Life Sciences, visit http://realtalifesciences.com/

Contact:
Ulrich Thienel, Chief Executive Officer
757-901-0454
https://www.linkedin.com/in/thienel/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved